More on NVO
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $37.40 |
|
|||
| Open | $37.63 | ||||
| 52 Wk High | $59.00 | ||||
| 52 Wk Low | $32.80 | ||||
| Day High | $37.65 | ||||
| Day Low | $37.17 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 10,326,086 | ||||
- BTIG survey finds GLP-1 users cut 500 calories daily from diet
- Novo Nordisk Wegovy data shows liver fat reduction in obesity trial
- Novo Nordisk shares new CagriSema brain and metabolic study data
- Novo Nordisk study shows weight loss in patients switching to oral Wegovy
- BMO Capital Reiterates Market Perform Rating on Novo Nordisk (NVO)
- Novo Nordisk licenses oral GLP-1/GIP dual agonist from Hengrui Pharma
- Novo Nordisk study links semaglutide 2 mg to lower heart risk vs tirzepatide
- Form 6-K NOVO NORDISK A S For: Sep 28
- CMS pumps $51M into rural Texas to fight diabetes and obesity
- Viatris sues Novo Nordisk over generic Wegovy patent dispute
Entities mentioned with NVO
- ARK | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Maynard Um | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- Options | View Related Stories »
- Show More...
